Skip to content

Comment on What's going on with gene therapies?parent

Comments

isn't that exactly what article is saying?

Bluebird Bio, once a leader with three FDA-approved gene therapies, sold itself to private equity for around $30 million earlier this year, a 99.7% decline from their all-time-high $10b valuation

*investment* is there, market isn't

AboutSource Built by g1lg1l

Hackerly is an independent reader for Hacker News, built on the public HN API. Not affiliated with Y Combinator.